No Data
Salubris Pharmaceuticals Gets Nod to Trial Enadostat Tablets
Shenzhen Salubris Pharmaceuticals (002294.SZ): Enadastride receives clinical trial approval for new indications.
Recently, Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that it has received the Clinical Trial Approval Notice approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials of Enaroytstat for a new indication (treatment of anemia caused by chemotherapy in non-myeloid malignancies, referred to as CIA). Enaroytstat (Enalor) is a new generation of domestic hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) drugs and is currently approved for the treatment of anemia in adult chronic kidney disease (CKD) patients who are not on hemodialysis. The indication newly applied for by the company is
Shenzhen Salubris Pharmaceuticals (002294.SZ): SAL0120 tablet approved for clinical trials to treat chronic kidney disease (CKD).
Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that it recently received the approval and issuance of the National Medical Products Administration's "..."
Investors in Shenzhen Salubris Pharmaceuticals (SZSE:002294) Have Seen Favorable Returns of 41% Over the Past Five Years
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Could Signal Some Risk
Shenzhen Salubris Pharmaceuticals (002294.SZ): The listing application of its subsidiary SAL056 has been accepted.
On June 25th, Gelonhui reported that Shenzhen Salubris Pharmaceuticals(002294.SZ) learned recently that its subsidiary, Suzhou Shenzhen Salubris Pharmaceuticals, had its biologic drug "Injectable Teriparatide" (project code: SAL056) application for listing accepted by the National Medical Products Administration. SAL056 is a long-acting bone formation stimulator that is subcutaneously injected once a week. It is intended for the treatment of postmenopausal women with osteoporosis at high risk of fracture. Currently, there are no products of the same specifications and dosage domestically. If SAL056 is approved for listing, it will greatly improve the convenience of patient medication.
No Data
